Abbott Laboratories

{
  "main_header": {
    "sid": 1149706,
    "name": "Abbott Laboratories",
    "stock_name": "Abbott Laboratories",
    "full_name": "Abbott Laboratories",
    "name_url": "stocks-analysis/abbott-laboratories",
    "exchange": 1,
    "exchangecode": "NYS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "121.14",
    "chg": -12.26,
    "chgp": "-9.19%",
    "dir": -1,
    "prev_price": "133.40",
    "mcapval": "258,487.47",
    "mcap": "Large Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2325,
    "indexname": "S&P 500",
    "isin": "US0028241000",
    "curr_date": "Jan 20",
    "curr_time": "",
    "bse_nse_vol": "6.64 M",
    "exc_status": "Active",
    "traded_date": "Jan 20, 2026",
    "traded_date_str": "2026 01 20",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/abbott-laboratories-1149706-1&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is Abbott Laboratories overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-abbott-laboratories-overvalued-or-undervalued-3728312",
        "imagepath": "",
        "date": "2025-11-25 11:13:52",
        "description": "As of 21 November 2025, the valuation grade for Abbott Laboratories has moved from very attractive to attractive. The company appears to be fairly valued based on its current metrics. Key ratios include a P/E ratio of 19, an EV to EBITDA of 25.84, and a PEG ratio of 0.14, indicating strong growth potential relative to its price.\n\nIn comparison to its peers, Abbott Laboratories has a more favorable P/E ratio of 18.36 compared to Thermo Fisher Scientific's 30.06 and Medtronic's 21.47, suggesting that it is priced more competitively within the industry. Despite a recent decline in stock price, Abbott has outperformed the S&P 500 year-to-date with a return of 12.45% compared to the index's 12.26%, although it has lagged significantly over the longer three and five-year periods...."
      },
      {
        "title": "Is Abbott Laboratories overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-abbott-laboratories-overvalued-or-undervalued-3723306",
        "imagepath": "",
        "date": "2025-11-23 11:09:25",
        "description": "As of 21 November 2025, the valuation grade for Abbott Laboratories has moved from very attractive to attractive. The company appears to be fairly valued based on its current metrics. Key ratios include a P/E ratio of 19, an EV to EBITDA of 25.84, and a PEG ratio of 0.14, indicating a strong growth potential relative to its price.\n\nIn comparison to peers, Abbott's P/E ratio of 18.36 is significantly lower than that of Thermo Fisher Scientific at 30.06 and Stryker Corp. at 33.17, suggesting it is more attractively priced in the market. Additionally, while Abbott's one-year return of 9.25% lags behind the S&P 500's 11.00%, its year-to-date return of 13.26% exceeds the S&P's 12.26%, reinforcing a positive outlook despite the longer-term underperformance...."
      }
    ],
    "total": 12,
    "sid": "1149706",
    "stock_news_url": "https://www.marketsmojo.com/news/abbott-laboratories-1149706"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Is Abbott Laboratories overvalued or undervalued?

2025-11-25 11:13:52

As of 21 November 2025, the valuation grade for Abbott Laboratories has moved from very attractive to attractive. The company appears to be fairly valued based on its current metrics. Key ratios include a P/E ratio of 19, an EV to EBITDA of 25.84, and a PEG ratio of 0.14, indicating strong growth potential relative to its price. In comparison to its peers, Abbott Laboratories has a more favorable P/E ratio of 18.36 compared to Thermo Fisher Scientific's 30.06 and Medtronic's 21.47, suggesting that it is priced more competitively within the industry. Despite a recent decline in stock price, Abbott has outperformed the S&P 500 year-to-date with a return of 12.45% compared to the index's 12.26%, although it has lagged significantly over the longer three and five-year periods....

Read full news article

Is Abbott Laboratories overvalued or undervalued?

2025-11-23 11:09:25

As of 21 November 2025, the valuation grade for Abbott Laboratories has moved from very attractive to attractive. The company appears to be fairly valued based on its current metrics. Key ratios include a P/E ratio of 19, an EV to EBITDA of 25.84, and a PEG ratio of 0.14, indicating a strong growth potential relative to its price. In comparison to peers, Abbott's P/E ratio of 18.36 is significantly lower than that of Thermo Fisher Scientific at 30.06 and Stryker Corp. at 33.17, suggesting it is more attractively priced in the market. Additionally, while Abbott's one-year return of 9.25% lags behind the S&P 500's 11.00%, its year-to-date return of 13.26% exceeds the S&P's 12.26%, reinforcing a positive outlook despite the longer-term underperformance....

Read full news article

View All News